RENAE FURAR: Open Payments
NPI 1093273682 · AVONDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,254 in 65 payments from 22 companies in 2025. Trend: 2023 $799 · 2024 $1,354 · 2025 $1,254
Food & beverage: $1,254
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 14 | $186 |
| AstraZeneca Pharmaceuticals LP | 8 | $185 |
| Abbott Laboratories | 5 | $125 |
| Novo Nordisk Inc | 6 | $120 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $101 |
| Sumitomo Pharma America, Inc. | 3 | $65 |
| Aimmune Therapeutics, Inc. | 3 | $59 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $45 |
| Eisai Inc. | 2 | $37 |
| ABBVIE INC. | 2 | $37 |
Products named: Kerendia, OTEZLA, AIRSUPRA, FARXIGA, GEMTESA, ZENPEP, EVENITY, JOT DX.
Industry payments across AZ — which companies pay providers there.
